Thanks to a Horizon 2020 grant, 6 biotech companies are pool- ing their expertise to develop solid-form, thermostable vaccines that will be cheaper, safer and needle-free.

Bern, Switzerland – September 2016 —

The funding turned out to be only one of the advantages of the MACIVIVA project, says its Scientific Co- ordinator, Dr Sylvain Fleury, who is the Chief Scientific Officer of Mymetics SA. “An EU grant improves your visibility, net- work and access to manufacturing capa- bilities with other EU- based companies.”

Read the full press release here :

Press release Research Success Story